- Home
- HNRG vs AUTL Comparison
HNRG vs AUTL Comparison
Compare HNRG & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- AUTL
- Stock Information
- Founded
- HNRG 1949
- AUTL 2014
- Country
- HNRG United States
- AUTL United Kingdom
- Employees
- HNRG N/A
- AUTL N/A
- Industry
- HNRG Coal Mining
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNRG Energy
- AUTL Health Care
- Exchange
- HNRG Nasdaq
- AUTL Nasdaq
- Market Cap
- HNRG 551.9M
- AUTL 590.8M
- IPO Year
- HNRG N/A
- AUTL 2018
- Fundamental
- Price
- HNRG $10.99
- AUTL $1.95
- Analyst Decision
- HNRG Strong Buy
- AUTL Strong Buy
- Analyst Count
- HNRG 2
- AUTL 3
- Target Price
- HNRG $15.00
- AUTL $10.20
- AVG Volume (30 Days)
- HNRG 465.3K
- AUTL 1.2M
- Earning Date
- HNRG 03-12-2025
- AUTL 03-13-2025
- Dividend Yield
- HNRG N/A
- AUTL N/A
- EPS Growth
- HNRG N/A
- AUTL N/A
- EPS
- HNRG N/A
- AUTL N/A
- Revenue
- HNRG $429,359,000.00
- AUTL $10,091,000.00
- Revenue This Year
- HNRG N/A
- AUTL $851.88
- Revenue Next Year
- HNRG $7.22
- AUTL $220.57
- P/E Ratio
- HNRG N/A
- AUTL N/A
- Revenue Growth
- HNRG N/A
- AUTL 82.71
- 52 Week Low
- HNRG $4.33
- AUTL $1.87
- 52 Week High
- HNRG $14.00
- AUTL $6.63
- Technical
- Relative Strength Index (RSI)
- HNRG 46.83
- AUTL 37.49
- Support Level
- HNRG $10.80
- AUTL $1.92
- Resistance Level
- HNRG $11.50
- AUTL $2.15
- Average True Range (ATR)
- HNRG 0.60
- AUTL 0.12
- MACD
- HNRG 0.08
- AUTL 0.01
- Stochastic Oscillator
- HNRG 38.57
- AUTL 22.22
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.